308 related articles for article (PubMed ID: 33692962)
1. Case Report:
Wen Z; Xiong D; Zhang S; Liu J; Li B; Li R; Zhang H
Front Oncol; 2021; 11():645370. PubMed ID: 33692962
[TBL] [Abstract][Full Text] [Related]
2. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
4. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
Yun KM; Bazhenova LA
Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
[TBL] [Abstract][Full Text] [Related]
5. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
6. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.
Passaro A; Lazzari C; Karachaliou N; Spitaleri G; Pochesci A; Catania C; Rosell R; de Marinis F
Onco Targets Ther; 2016; 9():6361-6376. PubMed ID: 27799783
[TBL] [Abstract][Full Text] [Related]
7. A case of
Makuuchi Y; Hayashi H; Haratani K; Tanizaki J; Tanaka K; Takeda M; Sakai K; Shimizu S; Ito A; Nishio K; Nakagawa K
Oncotarget; 2018 May; 9(33):23315-23319. PubMed ID: 29796191
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
[No Abstract] [Full Text] [Related]
9. Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors.
Singh A; Chen H
Cancer Manag Res; 2020; 12():6615-6628. PubMed ID: 32821158
[TBL] [Abstract][Full Text] [Related]
10. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
11. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
12. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
14. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
[TBL] [Abstract][Full Text] [Related]
15. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
16. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.
Feng C; Zhou R; Liu F; Wang T; Liu S; Shao Y
Front Oncol; 2021; 11():700341. PubMed ID: 34490099
[TBL] [Abstract][Full Text] [Related]
17. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
Karachaliou N; Fernandez Bruno M; Bracht JWP; Rosell R
Onco Targets Ther; 2019; 12():4567-4575. PubMed ID: 31354290
[TBL] [Abstract][Full Text] [Related]
18. Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Beardslee T; Lawson J
J Adv Pract Oncol; 2018; 9(1):94-101. PubMed ID: 30564472
[TBL] [Abstract][Full Text] [Related]
19. The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Gristina V; La Mantia M; Iacono F; Galvano A; Russo A; Bazan V
Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33352844
[TBL] [Abstract][Full Text] [Related]
20. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]